- NRx Pharmaceuticals, Lotus Pharmaceuticals y Alvogen Inc. anuncian colaboración para desarrollar y comercializar NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals, dan Alvogen Inc. Mengumumkan Kolaborasi untuk Mengembangkan dan Mengomersialkan NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen Inc. kündigen Zusammenarbeit zur Entwicklung und Vermarktung von NRX-101 an
- NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen Inc. annoncent leur collaboration pour le développement et la commercialisation du NRX-101
- NRxファーマシューティカルズ (NRx Pharmaceuticals)、ロータス・ファーマシューティカルズ (Lotus Pharmaceuticals)、およびアルボジェン (Alvogen Inc.) がNRX-101の開発・商品化に向けた提携を発表
- NRx Pharmaceuticals와 Lotus Pharmaceuticals, Alvogen Inc., NRX-101 개발 및 상용화 위한 협업 발표
- NRx Pharmaceuticals, Lotus Pharmaceuticals และ Alvogen Inc. ประกาศความร่วมมือเพื่อพัฒนาและนำ NRX-101 เข้าสู่ตลาด
- NRx Pharmaceuticals、Lotus Pharmaceuticals 和 Alvogen Inc. 宣布合作开发和商业化 NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colaboração para desenvolver e comercializar o NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals dan Alvogen Inc. Mengumumkan Kerjasama untuk Membangunkan dan Mengkomersialkan NRX-101
More ▼
Key statistics
On Thursday, Lotus Pharmaceutical Co Ltd (1795:TAI) closed at 282.00, -19.31% below its 52-week high of 349.50, set on May 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 290.50 |
---|---|
High | 294.00 |
Low | 281.00 |
Bid | 281.50 |
Offer | 282.00 |
Previous close | 290.00 |
Average volume | 4.89m |
---|---|
Shares outstanding | 264.96m |
Free float | 128.90m |
P/E (TTM) | 18.51 |
Market cap | 76.84bn TWD |
EPS (TTM) | 15.67 TWD |
Annual div (ADY) | 3.46 TWD |
---|---|
Annual div yield (ADY) | 1.19% |
Div ex-date | Jul 05 2023 |
Div pay-date | Aug 01 2023 |
Data delayed at least 20 minutes, as of May 09 2024.
More ▼